EGLN2 and myeloid sarcoma: From the investigated gene variants, RAB4B-EGLN2 rs111833532 rare allele D-containing genotypes (II vs. ID + DD) showed a trend toward association with higher plasma 4-HNE in MS patients overall (0.06), but statistical significance was achieved in the plasma of PMS patients (p = 0.04) (Table 5).